SCHEMBL4839170

SCHEMBL4839170

CC(=O)NC1(c2ccccc2)CCN(CCC2c3ccccc3CCN2C(=O)c2cccc3ccccc23)CC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.41
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
DRD2 P14416 5/20 0.38
DRD3 P35462 5/20 0.38
DRD4 P21917 3/20 0.38
MTNR1B P49286 1/20 0.38
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
NCOR2 Q9Y618 1/20 0.37
NR1D1 P20393 3/20 0.37
TACR2 P21452 2/20 0.36
TACR1 P25103 1/20 0.36
TACR3 P29371 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4837408 0.92 CYP2C19 (0.47) ALDH1A1DRD2DRD3MTNR1BHDAC3
SCHEMBL4839655 0.84 OPRM1 (0.46) POLBALDH1A1KDM4EHPGDHSD17B10
SCHEMBL4839456 0.84 TACR3 (0.44) POLBDRD2DRD3DRD4TACR2
SCHEMBL4837665 0.83 DRD3 (0.43) POLBALDH1A1DRD2DRD3DRD4
SCHEMBL4836727 0.83 POLB (0.42) POLBALDH1A1KDM4EHPGDHSD17B10
SCHEMBL4830126 0.83 TACR3 (0.45) POLBDRD2DRD3TACR3
SCHEMBL4839492 0.83 CYP2C19 (0.49) POLBALDH1A1MTNR1BTACR3
SCHEMBL4833088 0.83 GRIN2C (0.46) POLBTACR2TACR1
SCHEMBL4837218 0.83 GRIN2C (0.46) TACR2TACR1TACR3
SCHEMBL4832889 0.83 CYP2C19 (0.48) POLBALDH1A1MTNR1BTACR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US claimed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US claimed
EP-1458714-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. Lundbeck A/S (DK) 2004-09-22 EP claimed
WO-2003051869-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. LUNDBECK A/S (DK) 2003-06-26 WO claimed
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US disclosed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US disclosed
EP-1458714-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. Lundbeck A/S (DK) 2004-09-22 EP disclosed
WO-2003051869-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. LUNDBECK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives KCNJ2, KCNK2, KCNJ11 POLB 4382/4885ALDH1A1 639/4885KDM4E 2206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.